BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 59 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,304,588 | -37.9% | 1,275,000 | -39.3% | 0.00% | 0.0% |
| Q3 2022 | $2,101,000 | +112.4% | 2,100,000 | +110.0% | 0.00% | – |
| Q2 2022 | $989,000 | +92.4% | 1,000,000 | +100.0% | 0.00% | – |
| Q3 2021 | $514,000 | -77.2% | 500,000 | -77.2% | 0.00% | -100.0% |
| Q1 2021 | $2,257,000 | +1120.0% | 2,193,000 | +1153.1% | 0.00% | – |
| Q3 2018 | $185,000 | -63.4% | 175,000 | -65.0% | 0.00% | -100.0% |
| Q2 2018 | $506,000 | -88.8% | 500,000 | -88.9% | 0.00% | -93.3% |
| Q3 2017 | $4,517,000 | – | 4,500,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
| PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
| Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
| SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
| PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
| RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
| KBC Group NV | 400,000 | $40,316,000 | 0.15% |
| PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
| MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |